Bio-Technology General Euflexxa 1% Sodium Hyaluronate

Pays: Singapour

Langue: anglais

Source: HSA (Health Sciences Authority)

Disponible depuis:

FERRING PHARMACEUTICALS PRIVATE LIMITED

classe:

Class D medical device

Fabriqué par:

Bio-Technology General (Israel) Ltd.

Domaine thérapeutique:

Orthopaedics

indications thérapeutiques:

EUFLEXXA is indicated for the treatment of pain caused by osteoarthritis of the knee, hip, temporomandibular, carpometacarpal, shoulder and ankle joints. EUFLEXXA aids in lubrication of the joint, allows for greater mobility and flexibility of the treated joint, and reduces pain in the affected joint.

Descriptif du produit:

Device System Info:[Sterile Medical Device], EUFLEXXA is packed in a single-use, aseptically-filled disposable sterile 2.25 ml syringe (nominal volume) containing either 1 ml or 2 ml of 1% microbial fermentation-derived NaHA in phosphate-buffered saline; Models: Euflexxa 1% Sodium Hyaluronate - 3 x 2ml, Euflexxa 1% Sodium Hyaluronate - 1 x 2ml

Date de l'autorisation:

2017-04-28